Boehringer Ingelheim opens Health Management Centre in China

Shanghai, China, 12 August 2019 - Boehringer Ingelheim, world leading animal health company, announces the opening of the Boehringer Ingelheim Health Management Centre (HMC), again boosting Boehringer Ingelheim’s investment in China. The HMC records the first of its kind established by a multinational animal health company in China. Designed for world leading veterinary reference laboratories, the centre integrates animal disease and health diagnostics as well as monitoring tools to maintain and enhance animal health.

Located in Shanghai's Zhangjiang Hi-Tech Park, the HMC has an investment of nearly 3 million euros in its first phase. It is a full service reference laboratory with all diagnostic disciplines to provide comprehensive diagnosis for animal diseases, with a total projected staff of 25. The veterinary reference laboratory of the HMC, containing a serology lab, a molecular biology lab and a bacteriology lab, is currently capable of detecting more than 10 animal pathogens. It comprises state-of-the-art design, functionality, safety, and is eco-responsible. Numerous high-tech components allow for rapid detection with maximum quality control.

In addition, the centre aims to build Boehringer Ingelheim customers’ own diagnostic capabilities and capacity, functioning both as a reference laboratory and training centre which will provide comprehensive training in laboratory management, quality control, diagnostic platforms and more. The HMC is China National Accreditation Service for Conformity Assessment (CNAS) accredited.

Dr. Stephan Lange, Head of Animal Health for China's Mainland, Hong Kong and Taiwan at Boehringer Ingelheim, shared: “The opening of the HMC is another milestone for Boehringer Ingelheim in China. The HMC forms an integral part of living our ‘in China for China’ commitment. It further strengthens our ability to provide services along the full value chain for Chinese customers and highlights our commitment to continue to invest in China. We hope to best manage animal health and maximise productivity and profitability for our customers, as well as contribute to the improvement of animal and human health.”

Boehringer Ingelheim Animal Health Business Unit

Boehringer Ingelheim is the second largest animal health business in the world, with net sales of almost 4 billion euros in 2018 and presence in more than 150 markets.

Across the globe, our 10,000 employees create the future of animal wellbeing through their daily work. We believe in prevention over treatment and therefore, we focus on developing innovative solutions in the field of vaccines, parasiticides and therapeutics. With a large portfolio of advanced, preventive healthcare products, tools and services, we support our customers in taking care of the health of their animals.

For more information visit: www.boehringer-ingelheim.com/animal-health

Boehringer Ingelheim

Improving the health of humans and animals is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients’ lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on www.boehringer-ingelheim.com or in our annual report: https://annualreport.boehringer-ingelheim.com.

Intended audiences:

This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business.